表紙
市場調查報告書

美國的非專利特殊注射劑市場分析與預測:各治療用途(腫瘤、癌症、心血管、中樞神經系統、感染疾病、自體免疫疾病)、地區 2014年∼2025年

U.S. Specialty Injectable Generics Market Analysis By Therapeutic Use (Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Autoimmune Disorders), And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 600800
出版日期 內容資訊 英文 76 Pages
商品交期: 2-3個工作天內
價格
Back to Top
美國的非專利特殊注射劑市場分析與預測:各治療用途(腫瘤、癌症、心血管、中樞神經系統、感染疾病、自體免疫疾病)、地區 2014年∼2025年 U.S. Specialty Injectable Generics Market Analysis By Therapeutic Use (Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Autoimmune Disorders), And Segment Forecasts, 2014 - 2025
出版日期: 2017年11月02日內容資訊: 英文 76 Pages
簡介

美國的非專利特殊注射劑市場,預計至2025年達到278億美元。對癌症,自體免疫疾病,肝炎及感染疾病的治療成本效益高的醫藥品的高需求,預期為非專利特殊注射劑廠商帶來大機會。

本報告提供美國的非專利特殊注射劑市場相關調查,市場概要,各治療用途、地區的市場趨勢,市場規模的變化與預測,市場成長、阻礙因素及市場機會分析,市場佔有率,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 調查手法和範圍

  • 2次資訊來源的清單

第2章 摘要整理

  • 市場概要

第3章 美國的非專利特殊注射劑市場趨勢與範圍

  • 成長促進、阻礙因素
  • 重要的市場機會
  • PET分析
  • 產業分析 - 波特的五力分析
  • 企業佔有率
  • 專利分析
  • 價格趨勢分析

第4章 美國的非專利特殊注射劑市場:各治療用途

  • 市場趨勢分析:各治療用途
  • 腫瘤、癌症
  • 心血管
  • 中樞神經系統
  • 感染疾病
  • 自體免疫疾病
  • 其他

第5章 競爭情形

  • 策略架構
  • 參與企業的區分
  • 企業簡介
目錄
Product Code: GVR-2-68038-014-9

The U.S. specialty injectable generics market is expected to reach USD 27.8 billion by 2025, according to a new report by Grand View Research, Inc. High demand for cost-effective drugs for the treatment of cancer, autoimmune diseases, hepatitis, and infectious diseases is expected to create huge opportunities for manufacturers of specialty injectable generics. This has also encouraged many insurance companies to provide reimbursement for these products due to their low cost. According to FDA, generic drugs cost 80% to 85% lesser than branded drugs.

The affordability of these products can be attributed to elimination of certain processes, such as clinical trials, advertising, and other promotional activities. Moreover, in certain cases, a group of generic manufacturers receive approval for the commercialization of a single product. This creates pricing pressure and elevates competition, thereby resulting in the availability of cost-effective generics.

In addition, existing branded specialty injectables are expensive, thus limiting their adoption in the previous years. Increasing penetration of generic versions of these drugs and the entry of a large number of companies into the market has increased price competition, and this has resulted in the availability of drugs at affordable prices for patients. This has positively impacted emerging & price-sensitive countries and raised the demand for specialty injectable generics in the U.S.

Further Key Findings From the Report Suggest:

  • Oncology accounted for the largest market share in 2016. This can be attributed to high cancer prevalence coupled with increasing number of ANDA approvals for its treatment
  • Central Nervous System is expected to grow at an exponential rate throughout the forecast period, which can be attributed to high need for specialty injectables in the treatment of neurological diseases. This is encouraging key generic manufacturers to enter this therapeutic area
  • Level of competition is high as key players are adopting strategies, such as the development of new products and strategic collaborations & agreements to gain competitive advantage
  • Key players are engaged in the establishment of extensive distribution systems and mergers &acquisitions to capture a larger share
  • Pfizer, Inc. captured the largest share in 2016 and is involved in developing advanced technologies and formularies for high-quality generics
  • One of the major deals of Pfizer, Inc. was the acquisition of Hospira, Inc. in 2015, following which it captured a greater share of the generic injectables market in the U.S.

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Country Market Calculation
    • 1.1.1 Country Market: Base Estimates
    • 1.1.2 Global Market: CAGR Calculation
  • 1.2 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 U.S. Specialty Injectable Generics Market Variables, Trends & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Rising number of off-patent specialty drugs
      • 3.1.1.2 Escalating demand for low cost specialty injectable generics
      • 3.1.1.3 Increasing prevalence of chronic diseases
      • 3.1.1.4 Growing number of mergers and acquisitions to expand specialty injectable generics portfolio
    • 3.1.2 Market Restraint Analysis
      • 3.1.2.1 Stringent regulatory framework for specialty injectable generics
      • 3.1.2.2 Adoption of risk mitigation strategies by branded drug competitors
  • 3.2 Key Opportunities Prioritized
  • 3.3 PET Analysis, by Factor (political & legal, economic, and technological)
  • 3.4 Industry Analysis - Porter's Five Forces Analysis
  • 3.5 U.S. Specialty Injectable Generics Market: Company Market Share Analysis, 2016
  • 3.6 Patent Analysis
  • 3.7 Pricing Trend Analysis, 2016

Chapter 4 U.S. Specialty Injectable Generics Market: Therapeutic Use Estimates & Trend Analysis

  • 4.1 U.S. specialty injectable generics market: Therapeutic use movement analysis
  • 4.2 Oncology
    • 4.2.1 Oncology market, 2014 - 2025 (USD Billion)
  • 4.3 Cardiovascular
    • 4.3.1 Cardiovascular market, 2014 - 2025 (USD Billion)
  • 4.4 CNS
    • 4.4.1 CNS market, 2014 - 2025 (USD Billion)
  • 4.5 Infectious Diseases
    • 4.5.1 Infectious diseases market, 2014 - 2025 (USD Billion)
  • 4.6 Autoimmune Disorders
    • 4.6.1 Autoimmune disorders market, 2014 - 2025 (USD Billion)
  • 4.7 Others
    • 4.7.1 Others market, 2014 - 2025 (USD Billion)

Chapter 5 Competitive Landscape

  • 5.1 Strategy framework
  • 5.2 Market participation categorization
  • 5.3 Market participation categorization
  • 5.4 Company Profiles
    • 5.4.1 Pfizer, Inc.
      • 5.4.1.1 Company overview
      • 5.4.1.2 Financial performance
      • 5.4.1.3 Product benchmarking
      • 5.4.1.4 Strategic initiatives
    • 5.4.2 Teva Pharmaceutical Industries Ltd.
      • 5.4.2.1 Company overview
      • 5.4.2.2 Financial performance
      • 5.4.2.3 Product benchmarking
      • 5.4.2.4 Strategic initiatives
    • 5.4.3 Novartis AG
      • 5.4.3.1 Company overview
      • 5.4.3.2 Financial performance
      • 5.4.3.3 Product benchmarking
      • 5.4.3.4 Strategic initiatives
    • 5.4.4 Mylan N.V.
      • 5.4.4.1 Company overview
      • 5.4.4.2 Financial performance
      • 5.4.4.3 Product benchmarking
      • 5.4.4.4 Strategic initiatives
    • 5.4.5 Uman Pharma
      • 5.4.5.1 Company overview
      • 5.4.5.2 Product benchmarking
      • 5.4.5.3 Strategic initiatives
    • 5.4.6 Fresenius SE & Co. KGaA
      • 5.4.6.1 Company overview
      • 5.4.6.2 Financial performance
      • 5.4.6.3 Product benchmarking
      • 5.4.6.4 Strategic initiatives
    • 5.4.7 Baxter
      • 5.4.7.1 Company overview
      • 5.4.7.2 Financial performance
      • 5.4.7.3 Product benchmarking
      • 5.4.7.4 Strategic initiatives
    • 5.4.8 Par Pharmaceutical
      • 5.4.8.1 Company overview
      • 5.4.8.2 Financial performance
      • 5.4.8.3 Product benchmarking
      • 5.4.8.4 Strategic initiatives
    • 5.4.9 Sagent Pharmaceuticals, Inc.
      • 5.4.9.1 Company overview
      • 5.4.9.2 Financial performance
      • 5.4.9.3 Product benchmarking
      • 5.4.9.4 Strategic initiatives
    • 5.4.10 Teligent
      • 5.4.10.1 Company overview
      • 5.4.10.2 Financial performance
      • 5.4.10.3 Product benchmarking
      • 5.4.10.4 Strategic initiatives
    • 5.4.11 Hikma Pharmaceuticals PLC
      • 5.4.11.1 Company overview
      • 5.4.11.2 Financial performance
      • 5.4.11.3 Product benchmarking
      • 5.4.11.4 Strategic initiatives

List of Tables

  • TABLE 1 U.S. specialty injectable generics market, by therapeutic use, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market summary
  • FIG. 2 Market trends & outlook
  • FIG. 3 Market segmentation& scope
  • FIG. 4 Market driver relevance analysis (Current & future impact)
  • FIG. 5 Market restraint relevance analysis (Current & future impact)
  • FIG. 6 Key opportunities prioritized
  • FIG. 7 PET Analysis, by Factor (political & legal, economic, and technological)
  • FIG. 8 U.S. Specialty Injectable Generics - Porter's Five Forces Analysis
  • FIG. 9 Company market share analysis, 2016
  • FIG. 10 U.S. specialty injectable generics market, therapeutic use outlook: key takeaways
  • FIG. 11 U.S. specialty injectable generics market: Therapeutic use movement analysis
  • FIG. 12 U.S. oncology market, 2014 - 2025 (USD Billion)
  • FIG. 13 U.S. cardiovascular market, 2014 - 2025 (USD Billion)
  • FIG. 14 U.S. CNS market, 2014 - 2025 (USD Billion)
  • FIG. 15 U.S. infectious diseases market, 2014 - 2025 (USD Billion)
  • FIG. 16 U.S. autoimmune disorders market, 2014 - 2025 (USD Billion)
  • FIG. 17 U.S. others market, 2014 - 2025 (USD Million)
  • FIG. 18 Strategy framework
  • FIG. 19 Participant categorization
Back to Top